

2018 New Required Data Items for Hospitals



The NJSCR is a population-based registry, mandated by state law, that collects data on all cancer cases diagnosed and/or treated in New Jersey since October 1, 1978. It is a member of the North American Association of Central Cancer Registries (NAACCR), the National Program of Cancer Registries (NPCR). **This document is a list of the new data fields that are required by the NJSCR for cancer cases diagnosed starting 1/1/2018 based on the requirements of its standard setting organizations.** The data items are listed in alphabetical order. All health care facilities, physician, dentists, labs, ambulatory care facilities and other health care providers that diagnose, provide treatment or palliative care for cancer patients with active disease, must report cancer cases to the NJSCR.

For more information on required fields by standard setter visit: <http://datadictionary.naacr.org/?c=8>

For individual site specific data items (SSDI) with explanations visit: <https://apps.naacr.org/ssdi/list/>

Key for Codes.....2
 2018 NJ Required Table for Hospitals- All New.....3
 2018 NJ Requirements New SSDI Only.....7
 2018 NJ Required Non SSDI Only.....11

Table of Contents

Key:	
R	Required
R*	Required, when available

2018 NJ Required Table for Hospitals- New

		NJSCR
Item #	Item Name	Collect
3803	Adenoid Cystic Basaloid Pattern	R
3804	Adenopathy	R
3805	AFP Post-Orchiectomy Lab Value	R
3807	AFP Pre-Orchiectomy Lab Value	R
3810	AFP Pretreatment Lab Value	R
3811	Anemia	R
3812	B symptoms	R
3813	Bilirubin Pretreatment Total Lab Value	R
3814	Bilirubin Pretreatment Unit of Measure	R
3815	Bone Invasion	R
3816	Brain Molecular Markers	R
3817	Breslow Tumor Thickness	R
3818	CA-125 Pretreatment Interpretation	R
3819	CEA Pretreatment Interpretation	R
3820	CEA Pretreatment Lab Value	R
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	R
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	R
3821	Chromosome 3 Status	R
3822	Chromosome 8q Status	R
3823	Circumferential Resection Margin (CRM)	R
3824	Creatinine Pretreatment Lab Value	R
3825	Creatinine Pretreatment Unit of Measure	R
832	Date of Sentinel Lymph Node Biopsy	R*
682	Date Regional Lymph Node Dissection	R
683	Date Regional Lymph Node Dissection Flag	R
833	Date Sentinel Lymph Node Biopsy Flag	R*
776	EOD Mets	R
772	EOD Primary Tumor	R
774	EOD Regional Nodes	R
3829	Esophagus and EGJ Tumor Epicenter	R
3827	Estrogen Receptor Summary	R
3828	Estrogen Receptor Total Allred Score	R*
3830	Extranodal Extension Clin (non-Head and Neck)	R
3831	Extranodal Extension Head and Neck Clinical	R
3832	Extranodal Extension Head and Neck Pathological	R
3833	Extranodal Extension Path (non-Head and Neck)	R
3834	Extravascular Matrix Patterns	R
3835	Fibrosis Score	R
3836	FIGO Stage	R
3837	Gestational Trophoblastic Prognostic Scoring Index	R

2018 NJ Required Table for Hospitals- New (Cont.)		
3838	Gleason Patterns Clinical	R
3839	Gleason Patterns Pathological	R
3840	Gleason Score Clinical	R
3841	Gleason Score Pathological	R
3843	Grade Clinical	R
3844	Grade Pathological	R
3845	Grade Post Therapy	R
3846	hCG Post-Orchiectomy Lab Value	R
3847	hCG Post-Orchiectomy Range	R
3848	hCG Pre-Orchiectomy Lab Value	R
3849	hCG Pre-Orchiectomy Range	R
3850	HER2 IHC Summary	R*
3851	HER2 ISH Dual Probe Copy Number	R*
3852	HER2 ISH Dual Probe Ratio	R*
3853	HER2 ISH Single Probe Copy Number	R*
3854	HER2 ISH Summary	R*
3855	HER2 Overall Summary	R
3856	Heritable Trait	R
3857	High Risk Cytogenetics	R
3858	High Risk Histologic Features	R
3859	HIV Status	R
3860	International Normalized Ratio Prothrombin Time	R
3864	Invasion Beyond Capsule	R
3861	Ipsilateral Adrenal Gland Involvement	R
3862	JAK2	R
3863	Ki-67	R
3866	KRAS	R
3867	LDH Post-Orchiectomy Range	R
3868	LDH Pre-Orchiectomy Range	R
3932	LDH Pretreatment Lab Value	R
3869	LDH Pretreatment Level	R
3871	LN Assessment Method Femoral-Inguinal	R
3872	LN Assessment Method Para-Aortic	R
3873	LN Assessment Method Pelvic	R
3874	LN Distant Assessment Method	R
3875	LN Distant: Mediastinal Scalene	R
3876	LN Head and Neck Levels I-III	R
3877	LN Head and Neck Levels IV-V	R
3878	LN Head and Neck Levels VI-VII	R
3879	LN Head and Neck Other	R
3880	LN Isolated Tumor Cells (ITC)	R
3881	LN Laterality	R
3882	LN Positive Axillary Level I-II	R

2018 NJ Required Table for Hospitals- New (Cont.)		
3883	LN Size	R
3884	LN Status Femoral-Inguinal Para-Aortic Pelvic	R
3885	Lymphocytosis	R
3886	Major Vein Involvement	R
3887	Measured Basal Diameter	R
3888	Measured Thickness	R
2315	Medicare Beneficiary Identifier	R*
3889	Methylation of O6-Methylguanine-Methyltransferase	R
3890	Microsatellite Instability (MSI)	R*
3891	Microvascular Density	R
3892	Mitotic Count Uveal Melanoma	R
3893	Mitotic Rate Melanoma	R
3894	Multigene Signature Method	R
3895	Multigene Signature Results	R
3896	NCCN International Prognostic Index (IPI)	R
3897	Number of Cores Examined	R
3898	Number of Cores Positive	R
3899	Number of Examined Para-Aortic Nodes	R
3900	Number of Examined Pelvic Nodes	R
1532	Number of Phases of Rad Treatment to this Volume	R*
3901	Number of Positive Para-Aortic Nodes	R
3902	Number of Positive Pelvic Nodes	R
3903	Oncotype Dx Recurrence Score-DCIS	R
3904	Oncotype Dx Recurrence Score-Invasive	R
3905	Oncotype Dx Risk Level-DCIS	R
3907	Organomegaly	R
2078	Over-ride Name/Sex	R
3908	Percent Necrosis Post Neoadjuvant	R
3909	Perineural Invasion	R
3910	Peripheral Blood Involvement	R
3911	Peritoneal Cytology	R
1501	Phase I Dose per Fraction	R*
1503	Phase I Number of Fractions	R*
1502	Phase I Radiation External Beam Planning Tech	R*
1504	Phase I Radiation Primary Treatment Volume	R*
1505	Phase I Radiation to Draining Lymph Nodes	R*
1506	Phase I Radiation Treatment Modality	R
1507	Phase I Total Dose	R*
1511	Phase II Dose per Fraction	R*
1513	Phase II Number of Fractions	R*
1512	Phase II Radiation External Beam Planning Tech	R*
1514	Phase II Radiation Primary Treatment Volume	R*
1515	Phase II Radiation to Draining Lymph Nodes	R*

2018 NJ Required Table for Hospitals- New (Cont.)		
1516	Phase II Radiation Treatment Modality	R
1517	Phase II Total Dose	R*
1521	Phase III Dose per Fraction	R*
1523	Phase III Number of Fractions	R*
1522	Phase III Radiation External Beam Planning Tech	R*
1524	Phase III Radiation Primary Treatment Volume	R*
1525	Phase III Radiation to Draining Lymph Nodes	R*
1526	Phase III Radiation Treatment Modality	R
1527	Phase III Total Dose	R*
3913	Pleural Effusion	R
3918	Profound Immune Suppression	R
3915	Progesterone Receptor Summary	R
3916	Progesterone Receptor Total Allred Score	R*
3919	Prostate Pathological Extension	R
3920	PSA (Prostatic Specific Antigen) Lab Value	R
1531	Radiation Treatment Discontinued Early	R*
3921	Residual Tumor Volume Post Cytoreduction	R
3922	Response to Neoadjuvant Therapy	R
3923	S Category Clinical	R
3924	S Category Pathological	R
3925	Sarcomatoid Features	R
3926	Schema Discriminator 1	R
3927	Schema Discriminator 2	R
3700	SEER Site Specific Factor 1	R
834	Sentinel Lymph Nodes Examined	R*
835	Sentinel Lymph Nodes Positive	R*
3929	Separate Tumor Nodules	R
3930	Serum Albumin Pretreatment Level	R
3931	Serum Beta-2 Microglobulin Pretreatment Level	R
764	Summary Stage 2018	R*
3933	Thrombocytopenia	R
1533	Total Dose	R*
3934	Tumor Deposits	R
3935	Tumor Growth Pattern	R
3936	Ulceration	R
3937	Visceral and Parietal Pleural Invasion	R

2018 NJ Requirements New SSDI		
		NJSCR
Item #	Item Name	Collect
3804	Adenopathy	R
3805	AFP Post-Orchiectomy Lab Value	R
3807	AFP Pre-Orchiectomy Lab Value	R
3810	AFP Pretreatment Lab Value	R
3811	Anemia	R
3812	B symptoms	R
3813	Bilirubin Pretreatment Total Lab Value	R
3814	Bilirubin Pretreatment Unit of Measure	R
3815	Bone Invasion	R
3816	Brain Molecular Markers	R
3817	Breslow Tumor Thickness	R
3818	CA-125 Pretreatment Interpretation	R
3819	CEA Pretreatment Interpretation	R
3820	CEA Pretreatment Lab Value	R
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	R
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	R
3821	Chromosome 3 Status	R
3822	Chromosome 8q Status	R
3823	Circumferential Resection Margin (CRM)	R
3824	Creatinine Pretreatment Lab Value	R
3825	Creatinine Pretreatment Unit of Measure	R
682	Date Regional Lymph Node Dissection	R*
683	Date Regional Lymph Node Dissection Flag	R
3829	Esophagus and EGJ Tumor Epicenter	R
3827	Estrogen Receptor Summary	R
3828	Estrogen Receptor Total Allred Score	R*
3830	Extranodal Extension Clin (non-Head and Neck)	R
3831	Extranodal Extension Head and Neck Clinical	R
3832	Extranodal Extension Head and Neck Pathological	R
3833	Extranodal Extension Path (non-Head and Neck)	R
3834	Extravascular Matrix Patterns	R
3835	Fibrosis Score	R
3836	FIGO Stage	R
3837	Gestational Trophoblastic Prognostic Scoring Index	R
3838	Gleason Patterns Clinical	R
3839	Gleason Patterns Pathological	R
3840	Gleason Score Clinical	R
3841	Gleason Score Pathological	R
3845	Grade Post Therapy	R
3846	hCG Post-Orchiectomy Lab Value	R

2018 NJ Requirements New SSDI (Cont.)		
3847	hCG Post-Orchiectomy Range	R
3848	hCG Pre-Orchiectomy Lab Value	R
3849	hCG Pre-Orchiectomy Range	R
3850	HER2 IHC Summary	R*
3851	HER2 ISH Dual Probe Copy Number	R*
3852	HER2 ISH Dual Probe Ratio	R*
3853	HER2 ISH Single Probe Copy Number	R*
3854	HER2 ISH Summary	R*
3855	HER2 Overall Summary	R
3856	Heritable Trait	R
3857	High Risk Cytogenetics	R
3858	High Risk Histologic Features	R
3859	HIV Status	R
3860	International Normalized Ratio Prothrombin Time	R
3864	Invasion Beyond Capsule	R
3861	Ipsilateral Adrenal Gland Involvement	R
3862	JAK2	R
3863	Ki-67	R
3866	KRAS	R
3867	LDH Post-Orchiectomy Range	R
3868	LDH Pre-Orchiectomy Range	R
3932	LDH Pretreatment Lab Value	R
3869	LDH Pretreatment Level	R
3871	LN Assessment Method Femoral-Inguinal	R
3872	LN Assessment Method Para-Aortic	R
3873	LN Assessment Method Pelvic	R
3874	LN Distant Assessment Method	R
3875	LN Distant: Mediastinal Scalene	R
3876	LN Head and Neck Levels I-III	R
3877	LN Head and Neck Levels IV-V	R
3878	LN Head and Neck Levels VI-VII	R
3879	LN Head and Neck Other	R
3880	LN Isolated Tumor Cells (ITC)	R
3881	LN Laterality	R
3882	LN Positive Axillary Level I-II	R
3883	LN Size	R
3884	LN Status Femoral-Inguinal Para-Aortic Pelvic	R
3885	Lymphocytosis	R
3886	Major Vein Involvement	R
3887	Measured Basal Diameter	R
3888	Measured Thickness	R
3889	Methylation of O6-Methylguanine-Methyltransferase	R
3890	Microsatellite Instability (MSI)	R*

2018 NJ Requirements New SSDI (Cont.)		
3891	Microvascular Density	R
3892	Mitotic Count Uveal Melanoma	R
3893	Mitotic Rate Melanoma	R
3894	Multigene Signature Method	R
3895	Multigene Signature Results	R
3896	NCCN International Prognostic Index (IPI)	R
3897	Number of Cores Examined	R
3898	Number of Cores Positive	R
3899	Number of Examined Para-Aortic Nodes	R
3900	Number of Examined Pelvic Nodes	R
1532	Number of Phases of Rad Treatment to this Volume	R*
3901	Number of Positive Para-Aortic Nodes	R
3902	Number of Positive Pelvic Nodes	R
3903	Oncotype Dx Recurrence Score-DCIS	R
3904	Oncotype Dx Recurrence Score-Invasive	R
3905	Oncotype Dx Risk Level-DCIS	R
3907	Organomegaly	R
3908	Percent Necrosis Post Neoadjuvant	R
3909	Perineural Invasion	R
3910	Peripheral Blood Involvement	R
3911	Peritoneal Cytology	R
3913	Pleural Effusion	R
3918	Profound Immune Suppression	R
3914	Progesterone Receptor Percent Positive or Range	R
3915	Progesterone Receptor Summary	R
3916	Progesterone Receptor Total Allred Score	R*
3919	Prostate Pathological Extension	R
3920	PSA (Prostatic Specific Antigen) Lab Value	R
3921	Residual Tumor Volume Post Cytoreduction	R
3922	Response to Neoadjuvant Therapy	R
3923	S Category Clinical	R
3924	S Category Pathological	R
3925	Sarcomatoid Features	R
3926	Schema Discriminator 1	R
3927	Schema Discriminator 2	R
3700	SEER Site Specific Factor 1	R
3929	Separate Tumor Nodules	R
3930	Serum Albumin Pretreatment Level	R
3931	Serum Beta-2 Microglobulin Pretreatment Level	R
3933	Thrombocytopenia	R
3934	Tumor Deposits	R
3935	Tumor Growth Pattern	R

2018 NJ Requirements New SSDI (Cont.)		
3936	Ulceration	R
3937	Visceral and Parietal Pleural Invasion	R

2018 NJ Required Non SSDI fields		
Item #	Item Name	NJSCR Collect
832	Date of Sentinel Lymph Node Biopsy	R*
776	EOD Mets	R
772	EOD Primary Tumor	R
774	EOD Regional Nodes	R
3843	Grade Clinical	R
3844	Grade Pathological	R
2315	Medicare Beneficiary Identifier	R*
1532	Number of Phases of Rad Treatment to this Volume	R*
2078	Over-ride Name/Sex	R
1501	Phase I Dose per Fraction	R*
1503	Phase I Number of Fractions	R*
1502	Phase I Radiation External Beam Planning Tech	R*
1504	Phase I Radiation Primary Treatment Volume	R*
1505	Phase I Radiation to Draining Lymph Nodes	R*
1506	Phase I Radiation Treatment Modality	R
1507	Phase I Total Dose	R*
1511	Phase II Dose per Fraction	R*
1513	Phase II Number of Fractions	R*
1512	Phase II Radiation External Beam Planning Tech	R*
1514	Phase II Radiation Primary Treatment Volume	R*
1515	Phase II Radiation to Draining Lymph Nodes	R*
1516	Phase II Radiation Treatment Modality	R
1517	Phase II Total Dose	R*
1521	Phase III Dose per Fraction	R*
1523	Phase III Number of Fractions	R*
1522	Phase III Radiation External Beam Planning Tech	R*
1524	Phase III Radiation Primary Treatment Volume	R*
1525	Phase III Radiation to Draining Lymph Nodes	R*
1526	Phase III Radiation Treatment Modality	R
1527	Phase III Total Dose	R*
1531	Radiation Treatment Discontinued Early	R*
834	Sentinel Lymph Nodes Examined	R*
835	Sentinel Lymph Nodes Positive	R*
764	Summary Stage 2018	R*
1533	Total Dose	R*